AU2002366364A1 - E2f and cancer therapy - Google Patents

E2f and cancer therapy

Info

Publication number
AU2002366364A1
AU2002366364A1 AU2002366364A AU2002366364A AU2002366364A1 AU 2002366364 A1 AU2002366364 A1 AU 2002366364A1 AU 2002366364 A AU2002366364 A AU 2002366364A AU 2002366364 A AU2002366364 A AU 2002366364A AU 2002366364 A1 AU2002366364 A1 AU 2002366364A1
Authority
AU
Australia
Prior art keywords
cancer therapy
cancer
therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002366364A
Other versions
AU2002366364A8 (en
Inventor
Debabrata Banerjee
Joseph R. Bertino
Alex Laon Scarborough
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Memorial Sloan Kettering Cancer Center
Original Assignee
Sloan Kettering Institute for Cancer Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sloan Kettering Institute for Cancer Research filed Critical Sloan Kettering Institute for Cancer Research
Publication of AU2002366364A1 publication Critical patent/AU2002366364A1/en
Publication of AU2002366364A8 publication Critical patent/AU2002366364A8/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2002366364A 2001-12-18 2002-12-17 E2f and cancer therapy Abandoned AU2002366364A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34190801P 2001-12-18 2001-12-18
US60/341,908 2001-12-18
PCT/US2002/040355 WO2003051312A2 (en) 2001-12-18 2002-12-17 E2f and cancer therapy

Publications (2)

Publication Number Publication Date
AU2002366364A1 true AU2002366364A1 (en) 2003-06-30
AU2002366364A8 AU2002366364A8 (en) 2003-06-30

Family

ID=23339510

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002366364A Abandoned AU2002366364A1 (en) 2001-12-18 2002-12-17 E2f and cancer therapy

Country Status (2)

Country Link
AU (1) AU2002366364A1 (en)
WO (1) WO2003051312A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0803352D0 (en) 2008-02-22 2008-04-02 Ntnu Technology Transfer As Oligopeptidic compounds and uses thereof
WO2010120931A2 (en) * 2009-04-14 2010-10-21 University Of Medicine And Dentistry Of New Jersey E2f as a target for treatment of hormone refractory prostate cancer
US9880150B2 (en) 2015-01-28 2018-01-30 Thomas Jefferson University E2F reporter melanoma cells

Also Published As

Publication number Publication date
WO2003051312A3 (en) 2003-10-30
AU2002366364A8 (en) 2003-06-30
WO2003051312A2 (en) 2003-06-26

Similar Documents

Publication Publication Date Title
AU2001264559A1 (en) Cancer gene determination and therapeutic screening using signature gene sets
AUPS054702A0 (en) Cancer therapy
AU2002320058A1 (en) Magnetic-nanoparticle conjugates and methods of use
AU2003215460A1 (en) Cancer associated protein kinases and their uses
AU2002319338A1 (en) Cancer specific oligosaccharide sequences and use thereof
AUPQ923100A0 (en) Treatment of prostate cancer
AU2002342053A1 (en) Pancreatic cancer diagnosis and therapies
AU2002359589A1 (en) Antenna and shield
AU2002335667A1 (en) Modified reoviral therapy
AU2002215111A1 (en) Ruthenium-aryl-compounds in cancer therapy
AU2002366364A1 (en) E2f and cancer therapy
AU2001257325A1 (en) Cancer treatment
AU2002366195A1 (en) Use of bisindolmaleimide and gemcitabine for the treatment of cancer
AU2003283339A1 (en) Cancer therapy determination
AU5552400A (en) Treatment of cancer
AUPQ367699A0 (en) Treatment of cancer
AU2002305138A1 (en) Methods and materials for cancer treatment
AU2002351382A1 (en) Combination cancer therapy
AU5632500A (en) Cancer associated antigens and uses therefor
AU2001289127A1 (en) Tumor treatment
AU2001257168A1 (en) Cancer treatment
AUPR956701A0 (en) Cancer diagnosis and therapy ii
AUPR491901A0 (en) Cancer diagnosis and therapy
AU2001237414A1 (en) Cancer treatment and prognosis
AU2002953516A0 (en) Genetic therapy and genetic modification

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase